DPx Holdings B.V. Reaches Definitive Agreement to Acquire Gallus BioPharmaceuticals
DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, is pleased to announce that it has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners. Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally. DPx Holdings is the parent company of Patheon, DSM Fine Chemicals and Banner Life